"Combination treatments of imatinib with astaxanthin and crocin efficiently ameliorate antioxidant status, inflammation and cell death progression in imatinib-resistant chronic myeloid leukemia cells".
Astaxanthin
Chronic myeloid leukemia
Crocin
Drug resistance
Imatinib
K562 cells
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
received:
03
10
2023
accepted:
08
12
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
epublish
Résumé
Imatinib resistance remains a major obstacle in the treatment of chronic myelogenous leukemia (CML). Crocin (CRC) and astaxanthin (ATX) are phytochemicals with anti-cancer properties. This study aimed to explore the effects of combination treatment of Imatinib with CRC and ATX on Imatinib-resistant K562 (IR-K562) cells. After the establishment of IR-K562 cells, growth inhibitory activity was determined by the MTT assay. To test the regeneration potential, a colony formation assay was performed. Cell cycle analyses were examined by flow cytometry. Cell injury was evaluated by lactate dehydrogenase (LDH) leakage. Real-time PCR was applied to assess the expression of IL6, TNF-α, STAT3, BAD, CASP3, TP53, and Bcl-2 genes. Caspase-3 activity was determined by a colorimetric assay. Antioxidant activity was measured using a diphenylpicrylhydrazyl (DPPH) assay. After 48 h of treatment, ATX (IC Our data suggest that IM shows better therapeutic efficacy at lower doses when combined with ATX and/or CRC.
Sections du résumé
BACKGROUND
BACKGROUND
Imatinib resistance remains a major obstacle in the treatment of chronic myelogenous leukemia (CML). Crocin (CRC) and astaxanthin (ATX) are phytochemicals with anti-cancer properties.
AIMS
OBJECTIVE
This study aimed to explore the effects of combination treatment of Imatinib with CRC and ATX on Imatinib-resistant K562 (IR-K562) cells.
METHODS AND RESULTS
RESULTS
After the establishment of IR-K562 cells, growth inhibitory activity was determined by the MTT assay. To test the regeneration potential, a colony formation assay was performed. Cell cycle analyses were examined by flow cytometry. Cell injury was evaluated by lactate dehydrogenase (LDH) leakage. Real-time PCR was applied to assess the expression of IL6, TNF-α, STAT3, BAD, CASP3, TP53, and Bcl-2 genes. Caspase-3 activity was determined by a colorimetric assay. Antioxidant activity was measured using a diphenylpicrylhydrazyl (DPPH) assay. After 48 h of treatment, ATX (IC
CONCLUSION
CONCLUSIONS
Our data suggest that IM shows better therapeutic efficacy at lower doses when combined with ATX and/or CRC.
Identifiants
pubmed: 38227060
doi: 10.1007/s11033-023-09135-4
pii: 10.1007/s11033-023-09135-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Soverini S, De Benedittis C, Mancini M, Martinelli G (2016) Best practices in chronic Myeloid Leukemia monitoring and management. Oncologist 21:626–633
doi: 10.1634/theoncologist.2015-0337
pubmed: 27032870
pmcid: 4861357
Cai H, Li L, Jiang J, Zhao C, Yang C (2019) Costunolide enhances sensitivity of K562/ADR chronic Myeloid Leukemia cells to doxorubicin through PI3K/Akt pathway. Phytother Res 33:1683–1688. https://doi.org/10.1002/ptr.6355
doi: 10.1002/ptr.6355
pubmed: 30937974
Zhao M, Yang C, Chai S, Yuan Y, Zhang J, Cao P, Wang Y, Xiao X, Wu K, Yan H, Liu J, Sun S (2021) Curcumol and FTY720 synergistically induce apoptosis and differentiation in chronic myelomonocytic Leukemia via multiple signaling pathways. Phytother Res 35:2157–2170. https://doi.org/10.1002/ptr.6968
doi: 10.1002/ptr.6968
pubmed: 33274566
Kang Y, Hodges A, Ong E, Roberts W, Piermarocchi C, Paternostro G (2014) Identification of drug combinations containing imatinib for treatment of BCR-ABL + leukemias. PLoS ONE 9:e102221
doi: 10.1371/journal.pone.0102221
pubmed: 25029499
pmcid: 4100887
Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A (2014) Potential mechanisms of Disease progression and management of advanced-phase chronic Myeloid Leukemia. Leuk Lymphoma 55:1451–1462
doi: 10.3109/10428194.2013.845883
pubmed: 24050507
Yenigül M, Akçok İ, Gencer Akçok EB (2022) Ethacrynic acid and cinnamic acid combination exhibits selective anticancer effects on K562 chronic Myeloid Leukemia cells. Mol Biol Rep 49:7521–7530
doi: 10.1007/s11033-022-07560-5
pubmed: 35585382
Abdulmawjood B, Roma-Rodrigues C, Baptista PV, Fernandes AR, Particle (2023) & Particle Systems Characterization. https://doi.org/10.1002/ppsc.202300090
Alves R, Santos D, Jorge J, Gonçalves AC, Catarino S, Girão H, Melo JB, Sarmento-Ribeiro AB (2023) Alvespimycin inhibits heat shock protein 90 and overcomes Imatinib Resistance in Chronic Myeloid Leukemia cell lines. Molecules 28:1210
doi: 10.3390/molecules28031210
pubmed: 36770876
pmcid: 9920317
Haznedaroglu IC (2015) Drug therapy in the progressed CML patient with multi-TKI failure. Mediterranean J Hematol Infect Dis. https://doi.org/10.4084/MJHID.2015.014
doi: 10.4084/MJHID.2015.014
Feriotto G, Marchetti P, Rondanin R, Tagliati F, Aguzzi S, Beninati S, Casciano F, Tabolacci C, Mischiati C (2023) Cytotoxicity of Isoxazole Curcumin analogs on chronic myeloid leukemia-derived K562 cell lines sensitive and resistant to Imatinib. Int J Mol Sci 24:2356
doi: 10.3390/ijms24032356
pubmed: 36768681
pmcid: 9916957
Saavedra-Leos MZ, Jordan-Alejandre E, López-Camarillo C, Pozos-Guillen A, Leyva-Porras C, Silva-Cázares MB (2021) Nanomaterial complexes enriched with natural compounds used in Cancer therapies: a perspective for clinical application. Front Oncol 11:1032. https://doi.org/10.3389/fonc.2021.664380
doi: 10.3389/fonc.2021.664380
Wattanathamsan O, Hayakawa Y, Pongrakhananon V (2019) Molecular mechanisms of natural compounds in cell death induction and sensitization to chemotherapeutic Drugs in Lung cancer. Phytother Res 33:2531–2547. https://doi.org/10.1002/ptr.6422
doi: 10.1002/ptr.6422
pubmed: 31293008
Kheyrandish S, Rastgar A, Hamidi M, Sajjadi SM, Sarab GA (2022) Evaluation of anti-tumor effect of the exopolysaccharide from new cold-adapted yeast, Rhodotorula mucilaginosa sp. GUMS16 on chronic Myeloid Leukemia K562 cell line. Int J Biol Macromol 206:21–28
doi: 10.1016/j.ijbiomac.2022.02.113
pubmed: 35217074
Ozkan T, Hekmatshoar Y, Pamuk H, Ozcan M, Yaman G, Yagiz GC, Akdemir C, Sunguroglu A (2021) Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells. Mol Biol Rep 48:1625–1631
doi: 10.1007/s11033-021-06141-2
pubmed: 33515349
Saraei R, Rahman HS, Soleimani M, Asghari-Jafarabadi M, Naimi A, Hassanzadeh A, Solali S (2022) Kaempferol sensitizes Tumor necrosis factor-related apoptosis-inducing ligand-resistance chronic myelogenous Leukemia cells to apoptosis. Mol Biol Rep 49:19–29
doi: 10.1007/s11033-021-06778-z
pubmed: 34820749
Talebpour A, Alipour R, Sajjadi SM, Osmani F, Sarab GA (2022) In Vitro cytotoxicity of Ferula Asafoetida Gum extract on human chronic myelogenous Leukemia K562 cells. Pharm Chem J 56:245–253
doi: 10.1007/s11094-022-02627-w
Binatti E, Zoccatelli G, Zanoni F, Donà G, Mainente F, Chignola R (2021) Effects of Combination treatments with astaxanthin-loaded microparticles and pentoxifylline on intracellular ROS and radiosensitivity of J774A. 1 macrophages. Molecules 26:5152
doi: 10.3390/molecules26175152
pubmed: 34500586
pmcid: 8433905
Zhang C, Xu Y, Wu S, Zheng W, Song S, Ai C (2022) Fabrication of astaxanthin-enriched colon-targeted alginate microspheres and its beneficial effect on dextran sulfate sodium-induced ulcerative Colitis in mice. Int J Biol Macromol 205:396–409. https://doi.org/10.1016/j.ijbiomac.2022.02.057
doi: 10.1016/j.ijbiomac.2022.02.057
pubmed: 35176325
Brendler T, Williamson EM (2019) Astaxanthin: how much is too much? A safety review. Phytother Res 33:3090–3111
doi: 10.1002/ptr.6514
pubmed: 31788888
Rajabi H, Jafari SM, Feizi J, Ghorbani M, Mohajeri SA (2021) Surface-decorated graphene oxide sheets with nanoparticles of chitosan-arabic gum for the separation of bioactive compounds: a case study for adsorption of crocin from saffron extract. Int J Biol Macromol 186:1–12
doi: 10.1016/j.ijbiomac.2021.07.037
pubmed: 34242644
Geromichalos GD, Papadopoulos T, Sahpazidou D, Sinakos Z (2014) Safranal, a Crocus sativus L constituent suppresses the growth of K-562 cells of chronic myelogenous Leukemia. In silico and in vitro study. Food Chem Toxicol 74:45–50
doi: 10.1016/j.fct.2014.09.001
pubmed: 25239662
Sun Y, Xu H-J, Zhao Y-X, Wang L-Z, Sun L-R, Wang Z, Sun X-F (2013) Crocin exhibits antitumor effects on human Leukemia HL-60 cells in vitro and in vivo. Evidence-Based Complement Altern Med. https://doi.org/10.1155/2013/690164
doi: 10.1155/2013/690164
Rezaee R, Jamialahmadi K, Zanjani BR, Mahmoudi M, Abnous K, Rabe SZT, Tabasi N, Zali M, Rezaee M, Amin B (2014) Crocin effects on human Myeloma cells regarding intracellular redox state, DNA fragmentation, and apoptosis or necrosis profile. Jundishapur J Nat Pharm Prod. https://doi.org/10.17795/jjnpp-20131
doi: 10.17795/jjnpp-20131
pubmed: 25625054
pmcid: 4302399
Shahraki S, Bahraini F, Mesbahzadeh B, Sayadi M, Sajjadi SM (2023) Glucose increases proliferation and chemoresistance in chronic Myeloid Leukemia via decreasing antioxidant properties of ω-3 polyunsaturated fatty acids in the presence of Iron. Mol Biol Rep 1–10. https://doi.org/10.1007/s11033-023-08891-7
Chou T-C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446
doi: 10.1158/0008-5472.CAN-09-1947
pubmed: 20068163
Elzaawely A, Tawata S (2012) Antioxidant activity of phenolic rich fraction obtained from Convolvulus arvensis L. leaves grown in Egypt. Asian J Crop Sci. https://doi.org/10.3923/ajcs.2012.32.40
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 – ∆∆CT method. Methods 25:402–408
doi: 10.1006/meth.2001.1262
pubmed: 11846609
Lyczek A, Berger B-T, Rangwala AM, Paung Y, Tom J, Philipose H, Guo J, Albanese SK, Robers MB, Knapp S (2021) Mutation in abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. Proc Natl Acad Sci 118(46):e2111451118. https://doi.org/10.1073/pnas.2111451118
doi: 10.1073/pnas.2111451118
pubmed: 34750265
pmcid: 8609647
Kirschner KM, Baltensperger K (2003) Erythropoietin promotes Resistance against the abl tyrosine kinase inhibitor Imatinib (STI571) in K562 Human Leukemia Cells11Swiss National Science Foundation grant 31-059124 and Swiss Cancer League grant SKL 778-2-1999. Note: current address of Dr. Karin M. Kirschner is at Johannes-Müller Institut fu̇r Physiologie, Charité-Universitätsmedizin Berlin, Campus Charité-Mitte, Tucholskystrasse 2, 10117 Berlin. Ger Mol cancer Res 1:970–980
Yang Y, Zhong F, Jiang J, Li M, Yao F, Liu J, Cheng Y, Xu S, Chen S, Zhang H (2023) Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells. Hematology 28:2244856
doi: 10.1080/16078454.2023.2244856
pubmed: 37594290
Shin J, Song M-H, Oh J-W, Keum Y-S, Saini RK (2020) Pro-oxidant actions of carotenoids in triggering apoptosis of cancer cells: a review of emerging evidence. Antioxidants 9:532
doi: 10.3390/antiox9060532
pubmed: 32560478
pmcid: 7346220
Rastgar A, Sayadi M, Anani-Sarab G, Sajjadi SM (2022) Astaxanthin decreases the growth-inhibitory dose of cytarabine and inflammatory response in the acute lymphoblastic Leukemia cell line NALM-6. Mol Biol Rep 49:6415–6422
doi: 10.1007/s11033-022-07452-8
pubmed: 35441937
Li X, Huang T, Jiang G, Gong W, Qian H, Zou C (2013) Synergistic apoptotic effect of crocin and cisplatin on osteosarcoma cells via caspase induced apoptosis. Toxicol Lett 221:197–204
doi: 10.1016/j.toxlet.2013.06.233
pubmed: 23830991
Gong X, Smith JR, Swanson HM, Rubin LP (2018) Carotenoid lutein selectively inhibits Breast cancer cell growth and potentiates the effect of chemotherapeutic agents through ROS-mediated mechanisms. Molecules 23(4):905. https://doi.org/10.3390/molecules23040905
doi: 10.3390/molecules23040905
pubmed: 29662002
pmcid: 6017803
Rausch JL, Boichuk S, Ali AA, Patil SS, Lee DM, Brown MF, Makielski KR, Liu Y, Taguchi T, Kuan S-F (2017) Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal Tumor (GIST) cells to imatinib mesylate. Oncotarget 8(3):4471–4483
doi: 10.18632/oncotarget.13882
pubmed: 27965460
El-Barghouthi MI, Hasan AS, Al-Awaida W, Al-Ameer HJ, Kaur J, Hayashibara KJ, Fleming J, Waknin J, Hayashibara S, Slewa M (2022) Novel therapeutic heterocycles as selective cyclooxygenase-2 inhibitors and anti-cancer agents: synthesis, in vitro bioassay screenings, and molecular docking studies. J Mol Struct 1263:133141
doi: 10.1016/j.molstruc.2022.133141
Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, Blasiak J, Skorski T (2006) BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108:319–327
doi: 10.1182/blood-2005-07-2815
pubmed: 16527898
pmcid: 1895841
Blasiak J, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T (2015) Reactive oxygen species and mitochondrial DNA damage and repair in BCR-ABL1 cells resistant to imatinib. BioResearch open Access 4:334–342
doi: 10.1089/biores.2015.0022
pubmed: 26309809
pmcid: 4509616
Niu T, Xuan R, Jiang L, Wu W, Zhen Z, Song Y, Hong L, Zheng K, Zhang J, Xu Q (2018) Astaxanthin induces the Nrf2/HO-1 antioxidant pathway in human umbilical vein endothelial cells by generating trace amounts of ROS. J Agric Food Chem 66:1551–1559
doi: 10.1021/acs.jafc.7b05493
pubmed: 29381356
Liang Y, Zheng B, Li J, Shi J, Chu L, Han X, Chu X, Zhang X, Zhang J (2020) Crocin ameliorates arsenic trioxide–induced cardiotoxicity via Keap1-Nrf2/HO-1 pathway: reducing oxidative stress, inflammation, and apoptosis. Biomed Pharmacother 131:110713. https://doi.org/10.1016/j.biopha.2020.110713
doi: 10.1016/j.biopha.2020.110713
pubmed: 32920515
Staurengo-Ferrari L, Badaro-Garcia S, Hohmann MS, Manchope MF, Zaninelli TH, Casagrande R, Verri WA Jr (2019) Contribution of Nrf2 modulation to the mechanism of action of analgesic and anti-inflammatory Drugs in pre-clinical and clinical stages. Front Pharmacol 9:1536
doi: 10.3389/fphar.2018.01536
pubmed: 30687097
pmcid: 6337248
Kohandel Z, Farkhondeh T, Aschner M, Samarghandian S (2021) Nrf2 a molecular therapeutic target for Astaxanthin. Biomed Pharmacother 137:111374
doi: 10.1016/j.biopha.2021.111374
pubmed: 33761600
Godugu C, Pasari LP, Khurana A, Anchi P, Saifi MA, Bansod SP, Annaldas S (2020) Crocin, an active constituent of Crocus sativus ameliorates cerulein induced pancreatic inflammation and oxidative stress. Phytother Res 34:825–835. https://doi.org/10.1002/ptr.6564
doi: 10.1002/ptr.6564
pubmed: 31769107
Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA (2008) Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7:3169–3175
doi: 10.1158/1535-7163.MCT-08-0314
pubmed: 18852120
pmcid: 2676735
Sayed D, Badrawy H, Gaber N, Khalaf MR (2014) p-Stat3 and bcr/abl gene expression in chronic Myeloid Leukemia and their relation to imatinib therapy. Leuk Res 38:243–250. https://doi.org/10.1016/j.leukres.2013.11.012
doi: 10.1016/j.leukres.2013.11.012
pubmed: 24374144
Gleixner KV, Schneeweiss MA, Herrmann H, Blatt K, Berger D, Eisenwort G, Greiner G, Byrgazov K, Hoermann G, Konopleva M (2016) Combined targeting of STAT3 and STAT5: a Novel Approach to Overcome Drug Resistance in Ph + cml. Haematologica 102(9):1519–1529. https://doi.org/10.3324/haematol.2016.163436
doi: 10.3324/haematol.2016.163436
Gayatri MB, Kancha RK, Behera A, Patchva D, Velugonda N, Gundeti S, Reddy ABM (2023) AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous Leukemia (CML) subjects. Cell Death Discovery 9(1):401. https://doi.org/10.1038/s41420-023-01700-x
doi: 10.1038/s41420-023-01700-x
pubmed: 37903788
pmcid: 10616083
Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ (2015) Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic Myeloid Leukemia. Leukemia 29:586–597
doi: 10.1038/leu.2014.245
pubmed: 25134459
Han JH, Ju JH, Lee YS, Park JH, Yeo IJ, Park MH, Roh YS, Han SB, Hong JT (2018) Astaxanthin alleviated ethanol-induced liver injury by inhibition of oxidative stress and inflammatory responses via blocking of STAT3 activity. Sci Rep 8:1–10
Messina CM, Manuguerra S, Renda G, Santulli A (2019) Biotechnological applications for the sustainable use of marine by-products: in vitro antioxidant and pro-apoptotic effects of astaxanthin extracted with supercritical co2 from Parapeneus Longirostris. Mar Biotechnol 21:565–576
doi: 10.1007/s10126-019-09904-y
Jahromi AS, Kargar M, Kafilzadeh F, Jamalidoust M, Moradzadeh M (2021) Crocin promotes apoptosis in human EBV-transformed B-lymphocyte via intrinsic pathway. Mediterranean J Hematol Infect Dis 1(131):e2021049. https://doi.org/10.4084/MJHID.2021.049
doi: 10.4084/MJHID.2021.049
Hormozi M, Ghoreishi S, Baharvand P (2019) Astaxanthin induces apoptosis and increases activity of antioxidant enzymes in LS-180 cells. Artif Cells Nanomed Biotechnol 47:891–895
doi: 10.1080/21691401.2019.1580286
pubmed: 30873887